Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Cheng Weng

Showing results (151-160 of 154) with videos related to

Pageof 16
Sort By:
You have reached the last page of results.This site can display upto 154 results.
Nutrients|February 11, 2023
Effects of Spermidine on Mouse Gut Morphology, Metabolites, and Microbial DiversityDong-Mei Jiang, Ze-Long Wang, Jia-Di Yang, et al.
Molecular Cancer Therapeutics|January 9, 2025
OBI-992, a Novel TROP2-Targeted Antibody-Drug Conjugate, Demonstrates Antitumor Activity in Multiple Cancer ModelsWan-Fen Li, Ming-Feng Chiang, Hao-Cheng Weng, et al.
Nature Communications|May 21, 2024
Prodrug-conjugated tumor-seeking commensals for targeted cancer therapyHaosheng Shen, Changyu Zhang, Shengjie Li, et al.
Molecular Cancer Therapeutics|August 5, 2025
Preclinical pharmacokinetic, pharmacodynamic, and safety profile of OBI-992: a novel TROP2-targeted antibody-drug conjugateChi-Sheng Shia, Shih-Ni Wen, Ren-Yu Hsu, et al.
Pageof 16

Showing results (151-160 of 154) with videos related to

Sort By:
Pageof 16
You have reached the last page of results.This site can display upto 154 results.
Nutrients|February 11, 2023
Effects of Spermidine on Mouse Gut Morphology, Metabolites, and Microbial DiversityDong-Mei Jiang, Ze-Long Wang, Jia-Di Yang, et al.
Molecular Cancer Therapeutics|January 9, 2025
OBI-992, a Novel TROP2-Targeted Antibody-Drug Conjugate, Demonstrates Antitumor Activity in Multiple Cancer ModelsWan-Fen Li, Ming-Feng Chiang, Hao-Cheng Weng, et al.
Nature Communications|May 21, 2024
Prodrug-conjugated tumor-seeking commensals for targeted cancer therapyHaosheng Shen, Changyu Zhang, Shengjie Li, et al.
Molecular Cancer Therapeutics|August 5, 2025
Preclinical pharmacokinetic, pharmacodynamic, and safety profile of OBI-992: a novel TROP2-targeted antibody-drug conjugateChi-Sheng Shia, Shih-Ni Wen, Ren-Yu Hsu, et al.
Pageof 16